Analytical Data
-
Gene name
CD146
- Application
-
Alternative Names
MCAM; MUC18; Melanoma Cell Adhesion Molecule; Cell surface glycoprotein P1H12; Melanoma-associated antigen A32; S-endo 1 endothelial-associated antigen
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43121
-
Expression Region
Asp324~Val565
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD146, also known as MCAM (Melanoma Cell Adhesion Molecule), is a transmembrane glycoprotein expressed on the surface of various cell types, including endothelial cells, smooth muscle cells, and certain immune cells. It plays a crucial role in cell adhesion, migration, and signaling, influencing processes such as angiogenesis, immune response, and tissue repair. The study of CD146 has gained attention due to its association with several pathological conditions, including cancer, where it is implicated in tumor progression and metastasis, as well as cardiovascular diseases. The recombinant protein form of CD146 presents a unique opportunity to better understand its functions and regulatory mechanisms. Researchers have been focusing on producing CD146 in a recombinant form to facilitate in vitro studies, enabling the exploration of its role in cell signaling pathways and interactions within the tumor microenvironment. Furthermore, the availability of CD146 recombinant protein could aid in the development of novel therapeutic strategies targeting CD146 to inhibit tumor growth or promote vascular stability. As the understanding of CD146's biology continues to evolve, its potential as a biomarker and therapeutic target remains a promising area of research in both oncology and regenerative medicine. The generation and characterization of CD146 recombinant protein is therefore essential for elucidating its functional roles and therapeutic potential, ultimately contributing to advances in disease management and treatment.
